Cat. #160578
RYDERY Peptide
Cat. #: 160578
Availability: Please enquire for quantities and pricing
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Andrzej Gamian ; Edmund Ziomek ; Danuta Witkowska ; Anna Ewelina JarzÄ b
Institute: Polski O?rodek Rozwoju Technologii (PORT) Polish Center for Technology Development
Tool Details
*FOR RESEARCH USE ONLY
- Tool name: RYDERY Peptide
- Alternate name: Shigella flexneri 3a OMP
- Sequence: RYDERY
- Cellular tissue localisation: Umbilical blood
- Description: The genus Shigella belongs to Gram-negative opportunistic human pathogens and is responsible for colonic infections. Symptoms of infection include lower abdominal pain, fever and bloody diarrhoea which may cause a life threatening dehydration. Bacterial diarrhoea is in third place world wide in terms of causes of juvenile mortality below the age of five years. Infant and child mortality due to bacterial infections are generally caused by low standards of sanitation pervasive in developing nations. Nevertheless, infections by pathogenic intestinal bacteria, including Shigella, also occur in developed nations. Here, a bigger problem consists of strains resistant to antibiotics. For this reason, healthcare authorities both in developing and developed nations are pushing for prevention, including vaccination. Thus far, no one has managed to produce a vaccine against opportunistic bacterial pathogens of the gastrointestinal tract.
Handling
- Shipping conditions: Dry Ice
Application Details
- Application notes: Adapted from WO2014073998: This is a protein of the external cell wall of Shigella flexneri 3a with a molecular mass of 38 kDa which is immunoreactive with human serum. One potential application, amongst others, is its possible use as a carrier for use in conjugate vaccines. It is an epitope recognized by umbilical blood antibodies specific against enterobacteria, which may be used in the production of vaccines against Enterobacteriaceae, particularly opportunistic gastrointestinal bacterial pathogens, particularly bacteria of the genus Shigella.
References
- JarzÄ b et al. 2013. PLoS One. 8(8):e70539. PMID: 23940590.
